Scientists Create Cancer-Fighting Immune Cells Directly Inside the Body Using Red Blood Cells

This groundbreaking study addresses a major challenge in cancer immunotherapy: how to safely and efficiently create cancer-fighting immune cells directly inside patients' bodies, rather than through complex and expensive external cell engineering processes.

Researchers developed an innovative delivery system called mRNA-LNP-Ery, which attaches genetic instructions (mRNA) to red blood cells. These modified red blood cells naturally travel to the spleen, where they deliver the genetic code to myeloid immune cells, programming them to become chimeric antigen receptor (CAR) cells that can recognize and attack specific cancer targets.

The team tested this approach in laboratory models, targeting cancer cells expressing HER2 or CD19 proteins. The engineered immune cells successfully migrated to tumors, eliminated cancer cells, and recruited additional immune fighters including T cells and natural killer cells. Remarkably, this method worked at one-tenth the typical mRNA dose while producing superior anti-tumor effects compared to conventional approaches.

For longevity and health optimization, this research represents a significant advancement toward more accessible and safer cancer treatments. The reduced dosing requirements and minimal toxicity suggest this approach could be suitable for preventive or maintenance therapies. The ability to repeatedly administer treatments without severe side effects opens possibilities for long-term immune system enhancement.

However, this research was conducted in laboratory models, and human trials are needed to confirm safety and effectiveness. The approach requires an intact spleen to function properly, limiting its application in some patients.